vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and BLACKLINE, INC. (BL). Click either name above to swap in a different company.
BLACKLINE, INC. is the larger business by last-quarter revenue ($183.2M vs $180.9M, roughly 1.0× AVANOS MEDICAL, INC.). BLACKLINE, INC. runs the higher net margin — 2.7% vs -0.7%, a 3.4% gap on every dollar of revenue. On growth, BLACKLINE, INC. posted the faster year-over-year revenue change (8.1% vs 0.7%). BLACKLINE, INC. produced more free cash flow last quarter ($26.1M vs $21.3M). Over the past eight quarters, BLACKLINE, INC.'s revenue compounded faster (7.9% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
BlackLine Systems, Inc., is an American enterprise software company that develops cloud-based services designed to automate and manage the entire financial close process as well as consolidation, invoice-to-cash, and intercompany accounting. The Los Angeles–based company has 17 offices worldwide.
AVNS vs BL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $183.2M |
| Net Profit | $-1.3M | $4.9M |
| Gross Margin | 47.5% | 75.2% |
| Operating Margin | 1.4% | 3.7% |
| Net Margin | -0.7% | 2.7% |
| Revenue YoY | 0.7% | 8.1% |
| Net Profit YoY | 99.7% | -91.3% |
| EPS (diluted) | $-0.02 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $183.2M | ||
| Q3 25 | $177.8M | $178.3M | ||
| Q2 25 | $175.0M | $172.0M | ||
| Q1 25 | $167.5M | $166.9M | ||
| Q4 24 | $179.6M | $169.5M | ||
| Q3 24 | $170.4M | $165.9M | ||
| Q2 24 | $171.7M | $160.5M | ||
| Q1 24 | $166.1M | $157.5M |
| Q4 25 | $-1.3M | $4.9M | ||
| Q3 25 | $-1.4M | $5.3M | ||
| Q2 25 | $-76.8M | $8.3M | ||
| Q1 25 | $6.6M | $6.1M | ||
| Q4 24 | $-397.3M | $56.4M | ||
| Q3 24 | $4.3M | $17.2M | ||
| Q2 24 | $1.8M | $76.7M | ||
| Q1 24 | $-900.0K | $10.8M |
| Q4 25 | 47.5% | 75.2% | ||
| Q3 25 | 48.4% | 75.1% | ||
| Q2 25 | 52.6% | 75.2% | ||
| Q1 25 | 53.6% | 75.5% | ||
| Q4 24 | 54.6% | 75.6% | ||
| Q3 24 | 54.5% | 75.2% | ||
| Q2 24 | 55.7% | 74.9% | ||
| Q1 24 | 57.1% | 75.2% |
| Q4 25 | 1.4% | 3.7% | ||
| Q3 25 | 0.1% | 4.3% | ||
| Q2 25 | -42.6% | 4.4% | ||
| Q1 25 | 6.1% | 2.1% | ||
| Q4 24 | -233.0% | 3.7% | ||
| Q3 24 | 7.0% | 5.0% | ||
| Q2 24 | 3.7% | 1.4% | ||
| Q1 24 | 2.4% | 1.1% |
| Q4 25 | -0.7% | 2.7% | ||
| Q3 25 | -0.8% | 3.0% | ||
| Q2 25 | -43.9% | 4.8% | ||
| Q1 25 | 3.9% | 3.6% | ||
| Q4 24 | -221.2% | 33.3% | ||
| Q3 24 | 2.5% | 10.4% | ||
| Q2 24 | 1.0% | 47.8% | ||
| Q1 24 | -0.5% | 6.9% |
| Q4 25 | $-0.02 | $0.07 | ||
| Q3 25 | $-0.03 | $0.09 | ||
| Q2 25 | $-1.66 | $0.13 | ||
| Q1 25 | $0.14 | $0.10 | ||
| Q4 24 | $-8.64 | $0.79 | ||
| Q3 24 | $0.09 | $0.27 | ||
| Q2 24 | $0.04 | $0.22 | ||
| Q1 24 | $-0.02 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $390.0M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $332.3M |
| Total Assets | $1.1B | $1.8B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $390.0M | ||
| Q3 25 | $70.5M | $419.9M | ||
| Q2 25 | $90.3M | $459.1M | ||
| Q1 25 | $97.0M | $479.5M | ||
| Q4 24 | $107.7M | $885.9M | ||
| Q3 24 | $89.0M | $725.3M | ||
| Q2 24 | $92.2M | $616.6M | ||
| Q1 24 | $75.8M | $331.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $332.3M | ||
| Q3 25 | $778.0M | $328.3M | ||
| Q2 25 | $776.3M | $414.0M | ||
| Q1 25 | $839.4M | $417.9M | ||
| Q4 24 | $828.5M | $446.7M | ||
| Q3 24 | $1.2B | $367.9M | ||
| Q2 24 | $1.2B | $325.8M | ||
| Q1 24 | $1.2B | $279.8M |
| Q4 25 | $1.1B | $1.8B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $1.0B | $1.8B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $1.7B | $1.7B | ||
| Q2 24 | $1.7B | $1.9B | ||
| Q1 24 | $1.7B | $2.1B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $26.7M |
| Free Cash FlowOCF − Capex | $21.3M | $26.1M |
| FCF MarginFCF / Revenue | 11.8% | 14.2% |
| Capex IntensityCapex / Revenue | 3.8% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 5.46× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $161.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $26.7M | ||
| Q3 25 | $14.0M | $63.8M | ||
| Q2 25 | $6.8M | $32.3M | ||
| Q1 25 | $25.7M | $46.7M | ||
| Q4 24 | $57.9M | $43.8M | ||
| Q3 24 | $23.0M | $55.9M | ||
| Q2 24 | $27.8M | $40.7M | ||
| Q1 24 | $-8.0M | $50.4M |
| Q4 25 | $21.3M | $26.1M | ||
| Q3 25 | $7.0M | $63.3M | ||
| Q2 25 | $-4.2M | $31.4M | ||
| Q1 25 | $19.0M | $40.8M | ||
| Q4 24 | $53.1M | $43.0M | ||
| Q3 24 | $20.0M | $55.5M | ||
| Q2 24 | $21.9M | $40.0M | ||
| Q1 24 | $-12.1M | $50.1M |
| Q4 25 | 11.8% | 14.2% | ||
| Q3 25 | 3.9% | 35.5% | ||
| Q2 25 | -2.4% | 18.2% | ||
| Q1 25 | 11.3% | 24.4% | ||
| Q4 24 | 29.6% | 25.4% | ||
| Q3 24 | 11.7% | 33.5% | ||
| Q2 24 | 12.8% | 24.9% | ||
| Q1 24 | -7.3% | 31.8% |
| Q4 25 | 3.8% | 0.3% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 6.3% | 0.6% | ||
| Q1 25 | 4.0% | 3.6% | ||
| Q4 24 | 2.7% | 0.4% | ||
| Q3 24 | 1.8% | 0.2% | ||
| Q2 24 | 3.4% | 0.4% | ||
| Q1 24 | 2.5% | 0.2% |
| Q4 25 | — | 5.46× | ||
| Q3 25 | — | 12.07× | ||
| Q2 25 | — | 3.90× | ||
| Q1 25 | 3.89× | 7.72× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | 5.35× | 3.24× | ||
| Q2 24 | 15.44× | 0.53× | ||
| Q1 24 | — | 4.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
BL
| Subscription And Circulation | $173.2M | 95% |
| Technology Service | $10.0M | 5% |
